Mahamaya Lifesciences IPO Listing: Shares of Mahamaya Sciences had a lackluster entry in the domestic market today. Its IPO received an overall bid of 1.63 times. Shares have been issued under the IPO at a price of ₹ 114.00. Today it has entered BSE SME at ₹ 116.00, which means IPO investors got a listing gain of 1.75% (Mahamaya Lifesciences Listing Gain). However, the joy of IPO investors soon faded as the shares crashed. After listing the shares went up further. It jumped and reached the upper circuit of ₹ 121.80 (Mahamaya Lifesciences Share Price) i.e. IPO investors are now in 6.84% profit.
How will Mahamaya Lifesciences IPO money be spent?
Mahamaya Lifesciences’ ₹70.44 crore IPO was open for subscription from November 11-13. This IPO received 1.63 times bids from investors. In this, the portion reserved for Qualified Institutional Buyers (QIB) was 1.19 times (ex-anchor), the portion for Non-Institutional Investors (NII) was 3.63 times and the portion for retail investors was 1.02 times. New shares worth ₹64.28 crore have been issued under this IPO. Apart from this, 5.40 lakh shares with face value of ₹ 10 have been sold under the offer for sale window.
The shareholders who sold the shares have received the money from the offer for sale. Of the money raised through new shares, ₹3.75 crore will be spent on purchase of equipment for the existing formulation plant, ₹29.42 crore will be spent on setup of new technical manufacturing plant, ₹2.53 crore will be spent on construction of warehouse building and purchase of machinery, ₹18.00 crore will be spent on working capital needs and the remaining money will be spent on general corporate purposes.
About Mahamaya Lifesciences
Mahamaya Lifesciences, established in the year 2002, manufactures formulas related to crop protection and soil health. It manufactures and supplies pesticides formulations in bulk to domestic and multinational companies. It imports researched molecules from abroad, then registers them with the Central Insecticides Board. After this, the company sells these to domestic and multinational companies in the form of technical and value-added formulations.
Talking about the financial health of the company, it has continuously strengthened. It had a net profit of ₹3.75 crore in FY 2023, which jumped to ₹5.22 crore in the next FY 2024 and ₹12.94 crore in FY 2025. During this period, the total income of the company increased at a compound growth rate (CAGR) of more than 39% annually to ₹ 267.17 crore. Talking about the current financial year 2026, in the first quarter April-June 2025, the company has achieved net profit of ₹ 4.10 crore and total income of ₹ 84.04 crore. At the end of June 2025 quarter, the company had a total debt of ₹57.72 crore while reserves and surplus were ₹35.73 crore.
Disclaimer: The information provided here is being provided for information only. It is important to mention here that investing in the market is subject to market risks. As an investor, always consult an expert before investing money. Moneycontrol never advises anyone to invest money here.